Indapril (indapamide/perindopril) / Incepta Pharma - LARVOL DELTA

Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "Lots of studies showed the combination therapy of perindopril, indapamide and amlodipine could increase BP lowering efficacy and the benefits of high-risk patients. The stability of analytes over different storage and processing conditions in the whole study was also validated. The method is fast, accurate, sensitive and reproducible, which is suitable for the detection of the concentration of perindopril, perindoprilat and indapamide in human plasma."

Journal • Hypertension

Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. (PubMed, Adv Ther) - "Switching to Per/Ind SPC led to rapid and effective BP decreases in patients with T2DM, obesity, or MetS. BP control was achieved in 6-7 out of 10 previously treated but uncontrolled patients. Treatment was well tolerated. The results confirm the beneficial effects of a Per/Ind SPC for difficult-to-control patient populations."

Journal • Observational data • Retrospective data • Diabetes • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

History of lower-limb complications and risk of cancer death in people with type 2 diabetes. (PubMed, Cardiovasc Diabetol) - "PAD and peripheral neuropathy were independently associated with increased 5-year risk of cancer death in individuals with type 2 diabetes. PAD was also associated with increased risk of incident cancers. Our findings provide new evidence on the non-cardiovascular prognostic burden of lower-limb complications in people with type 2 diabetes."

Journal • Cardiovascular • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Oncology • Pain • Peripheral Arterial Disease • Type 2 Diabetes Mellitus

Excellent Outcome of Protocol-Based Treatment of Motivated Type 2 Diabetes Mellitus (T2DM) Patients: A Real World Follow-Up for 11 Years. (PubMed, Cureus) - "Glycemic parameters (FPG, PPG, and HbA1c) and renal parameters (serum creatinine, eGFR, and ACR levels) remained stable. Our outcomes data were better than those recorded in the landmark United Kingdom Prospective Diabetes Study (UKPDS) and Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE)."

Clinical • Journal • Real-World Evidence • Diabetes • Dyslipidemia • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO Observational Studies. (PubMed, Adv Ther) - "In this hypertensive population including difficult-to-control patient subgroups, switching to Per/Ind 10/2.5 mg SPC led to rapid and important reductions in BP. BP control was achieved in 70% of patients overall in an everyday practice context."

Journal • Observational data • Retrospective data • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders

Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blinded randomized controlled trial. (PubMed, J Clin Hypertens (Greenwich)) - "A fixed initial combination of perindopril-amlodipine or perindopril-indapamide achieved similar effective BP control after 6 weeks in SSA type 2 diabetic individuals with newly diagnosed hypertension. Therefore, these combinations can be used interchangeably in this indication."

Clinical • Journal • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Economic Evaluation of a New Polygenic Risk Score to Predict Nephropathy in Adult Patients With Type 2 Diabetes. (PubMed, Can J Diabetes) - "This economic evaluation demonstrates that the PRS is a dominant option compared with usual screening methods for the prevention of DN in patients with T2D. Adoption of the PRS would reduce costs saving but would also help prevent ESRD and improve patients' quality of life."

Clinical • HEOR • Journal • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Effect of Perindopril/Indapamide on Cerebral Blood Flow in Middle-Aged, Treatment-Naïve Patients with Hypertension. (PubMed, Adv Ther) - "In middle-aged, treatment-naïve patients with hypertension, Pa/I SPC was associated with increased CBF in the cortical plate of the frontal lobes, which achieved levels of normotensive controls. The increase in CBF had no clear association with observed BP changes."

Clinical • Journal • Hypertension

Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. (PubMed, Clin J Am Soc Nephrol) - "Clinically meaningful decreases in eGFR and increases in UACR over 2 years, independently and in combination, were significantly associated with higher risk of major clinical outcomes."

Clinical • Clinical data • Journal • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Myocardial Infarction • Renal Disease • Type 2 Diabetes Mellitus

PRECIOUS: Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine (clinicaltrials.gov) - P4; N=471; Completed; Sponsor: KRKA; Active, not recruiting ➔ Completed

Clinical • Trial completion • Hypertension

[VIRTUAL] Mothers with post-partum hypertension and kidney damage after pre-eclampsia should receive ACE inhibitors rather than methyldopa (ESC 2020) - " In a case-control, open-label 1-year study, 54 post-partum women (aged 25–37 years) with grade 2 (53.7%) or 3 (46.3%) HT and kidney damage [48 patients (88.9%) had moderately increased albuminuria (30–299 mg/g), 6 (11.1%) – severely increased albuminuria (>300 mg/g), 32 (59.3%) – mildly decreased eGFR (60–89 mL/min/1.73 m2 (BSA)) and 3 (5,6%) – mildly to moderately decreased eGFR (45–59 mL/min/1.73 m2)] after early-onset PE (with delivery at <34+0 weeks of gestation) superimposed to HT received either adjusted-dose ACE inhibitors – ACEi (33 non-feeding mothers: 19 – perindopril, 5 – ramipril, 9 – perindopril and indapamide SR combination) or methyldopa (21 nursing women). Non-feeding women with grade 2 or 3 post-partum HT and renal damage after early-onset PE get greater heart, kidney and vessels benefits from 1-year ACEi treatment than nursing mothers from methyldopa."

Cardiovascular • Hypertension

The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. (PubMed, J Clin Endocrinol Metab) - "In the absence of substantial lifestyle changes, weight loss may be a warning sign of poor health meriting further work-up in patients with type 2 diabetes."

Clinical • Journal • Cardiovascular • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Antihypertensive and Vasoprotective Effects of Combined Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes (PubMed, Kardiologiia) - "After randomization using envelopes, three treatment groups were formed: group 1, patients receiving perindopril, indapamide SR, and metformin (n=40); group 2, patients receiving perindopril, moxonidin, and metformin (n=40); and group 3, patients receiving perindopril, indapamide SR, and amlodipine (n=40). In groups 2 and 3, the treatment was associated with significantly more pronounced beneficial changes in 24-BPM, arterial stiffness, and CAP compared to group 1. Antihypertensive and vasoprotective effects of the perindopril+moxonidin+metformin and perindopril+indopamide SR+amlodipine combinations were comparable.Conclusion The observed statistically significant antihypertensive and vasoprotective effects of the perindopril+moxonidin+metformin combination along with its known positive metabolic effect allow recommendation of this combination therapy to patients with AH and prediabetes as an effective strategy for BP control."

Clinical • Journal • Hypertension • Metabolic Disorders • Pulmonary Arterial Hypertension

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. (PubMed, Diabetologia) - P=N/A, P3 | "Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality."

Journal • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Alternative Kidney Filtration Markers and the Risk of Major Macrovascular and Microvascular Events, and All-Cause Mortality in Individuals with Type 2 Diabetes in the ADVANCE trial. (PubMed, J Diabetes) - "In adults with type 2 diabetes, baseline levels of eGFR based on alternative filtration markers and per 30% decline in eGFR , eGFR , and eGFR were associated with clinical outcomes. Measurement of alternative filtration markers, particularly B2M in adults with type 2 diabetes may be warranted."

Clinical • Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Renal Disease • Type 2 Diabetes Mellitus • B2M • CST3

Analysis of Preferences in the Use of Fixed-Doses Combinations Antihypertensive Drugs in the Regions of Far-Eastern Federal District. (PubMed, Clinicoecon Outcomes Res) - "The most acquired combinations were atenolol+chlorthalidone, valsartan+amlodipine, losartan+hydrochlorothiazide, perindopril/lisinopril/ramipril+amlodipine, perindopril+indapamide. Group leaders may vary depending on the region, which is due to the preferences of medical specialists. However, the differences are not significant, which proves the unity of approaches to combined drug therapy of arterial hypertension."

Journal • Hypertension • Pulmonary Arterial Hypertension

[VIRTUAL] The efficiency of eplerenon in complex treatment of the patients with arterial hypertension, atrial fibrillation and heart failure with preserved ejection fraction (HEART FAILURE-I 2020) - "Combination of perindopril + indapamide in a dose of 5/1.25-10/2.5 mg/day was given 65 (44.5%) and combination of losartan + hydrochlorothiazide in a dose of 50/12.5-100/25 mg/day – 81 (55.5%) patients. the appointment of 25 mg/day of eplerenone to basic antiarrhythmic and antihypertensive therapy significant reduces electrical instability for patients with AH and HFpEF."

Clinical • Cardiovascular • Dyslipidemia

Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice. (PubMed) - "FDTC of perindopril/indapamide/amlodipine was effective at reducing SBP and PP in previously treated patients with uncontrolled hypertension, and well tolerated, providing support for clinicians in choosing a fixed-dose triple combination over the free-combination of a RAAS inhibitor, a diuretic, and a calcium antagonist."

Journal • Biosimilar • Cardiovascular

Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. (PubMed, Diabetes Care) - "Microvascular disease, particularly macroalbuminuria and retinal photocoagulation therapy, strongly predicts major PAD in patients with type 2 diabetes, but macrovascular disease does not."

Journal • Atherosclerosis • Biosimilar • Cardiovascular • Diabetes • Dyslipidemia • Immunology • Metabolic Disorders • Ophthalmology • Renal Disease

Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes. (PubMed, Endocrine) - "This prospective cohort study showed that glycemic variability was significantly lower for GC than IC and PC. Furthermore, glycemic variability was associated with the risk of MACE and hypoglycemia in total patients and subgroups of different glycemic control."

Clinical • Journal

Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. (PubMed, Diabetologia) - P3 | "Plasma n-3 fatty acids and DHA were found to be inversely associated with macrovascular disease, while n-3 fatty acids were also inversely associated with death. These results support the cardioprotective effects of n-3 fatty acids and DHA and further merit testing the role of high-dose supplementation with n-3 fatty acids in individuals with type 2 diabetes."

Clinical • Journal

FITNESS: Fimasartan in the Senior Subjects (clinicaltrials.gov) - P3b; N=241; Completed; Sponsor: Boryung Pharmaceutical Co., Ltd; Recruiting ➔ Completed; Trial primary completion date: Feb 2018 ➔ Aug 2019

Clinical • Monotherapy • Trial completion • Trial primary completion date

The Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A in the ADVANCE Trial. (PubMed, Diabetes Care) - "The major benefits for patients with T2D in ADVANCE did not substantially differ across levels of baseline ASCVD risk and HbA."

Clinical • Clinical data • Journal

Kidney Filtration Markers and the Risk of Clinical Outcomes in Individuals With Type 2 Diabetes in the Advance Trial (EPI-LIFESTYLE 2020) - " In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, Cr, Cys, and B2M were measured in 7,217 participants at baseline and a random sample of 640 participants at the 1 year visit... In adults with type 2 diabetes, baseline levels of eGFR based on alternative filtration markers and per 30% decline in eGFRCys and eGFRavg were consistently associated with all clinical outcomes."

Clinical • Clinical data • B2M • CST3

Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. (PubMed, Hypertension) - P=N/A; "Cox models were used to determine whether baseline BP category or CVD risk modified the outcomes of combination perindopril-indapamide treatment, compared with placebo. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT00751972."

Clinical • Clinical data • Journal